Publications by authors named "Petr Kessler"

Claim this Profile
T
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Alexandra Jungova, Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Petr Kessler

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Petr Kessler

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Viera Sandecka, Luděk Pour, Ivan Špička, Jiří Minařík, Jakub Radocha, Petr Kessler

Neoplasma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease.
Erika Tarasco, Anne Sophie von Krogh, Radomira Hrdlickova, Thomas R Braschler, Teresa Iwaniec, Petr Kessler

Res Pract Thromb Haemost· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.
Jakub Radocha, Tomas Jelinek, Ludek Pour, Ivan Spicka, Jiri Minarik, Petr Kessler

Int J Lab Hematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Viera Sandecká, Luděk Pour, Ivan Špička, Jiří Minařík, Jakub Radocha, Petr Kessler

Eur J Haematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing clinical approaches to COVID-19 patients in primary care.
Bohumil Seifert, Martin Balík, Václava Bártů, Ludmila Bezdíčková, Vladimír Černý, Petr Kessler

Cas Lek Cesk· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Petr Kessler

BMC Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.
Martina Almasi, Lenka Besse, Lucie Brozova, Jiří Jarkovsky, Renata Bezdekova, Petr Kessler

Klin Onkol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Jakub Radocha, Vladimír Maisnar, Luděk Pour, Ivan Špička, Jiři Minařík, Petr Kessler

Cancer Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Roman Hájek, Jiri Jarkovsky, Vladimír Maisnar, Ludek Pour, Ivan Špička, Petr Kessler

Clin Lymphoma Myeloma Leuk· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
Tomáš Jelínek, Vladimír Maisnar, Luděk Pour, Ivan Špička, Jiří Minařík, Petr Kessler

Curr Med Res Opin· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Viera Sandecká, Roman Hájek, Luděk Pour, Ivan Špička, Vlastimil Ščudla, Petr Kessler

Eur J Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Long-term treatment of venous thromboembolism in patients with cancer].
Jan Šmrha, Petr Kessler, Hynek Poul, Michaela Harudová

Vnitr Lek· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Aneta Mikulasova, Jan Smetana, Marketa Wayhelova, Helena Janyskova, Viera Sandecka, Petr Kessler

Eur J Haematol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Petr Kessler

PLoS One· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis